Atrion (NASDAQ:ATRI) Downgraded to “Hold” at BidaskClub

Atrion (NASDAQ:ATRI) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

Shares of NASDAQ:ATRI opened at $877.80 on Tuesday. Atrion has a 1-year low of $571.00 and a 1-year high of $948.03. The firm has a market cap of $1.64 billion, a PE ratio of 46.75 and a beta of 0.40.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $5.07 earnings per share for the quarter. Atrion had a return on equity of 16.89% and a net margin of 22.76%. The firm had revenue of $41.61 million during the quarter.

In other news, Director Ronald Nicholas Spaulding sold 170 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $903.00, for a total transaction of $153,510.00. Following the completion of the transaction, the director now directly owns 2,158 shares in the company, valued at $1,948,674. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.07% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. Quadrant Capital Group LLC bought a new stake in Atrion in the 1st quarter worth about $27,000. O Shaughnessy Asset Management LLC bought a new stake in Atrion in the 1st quarter worth about $100,000. PNC Financial Services Group Inc. bought a new stake in Atrion in the 4th quarter worth about $130,000. Amundi Pioneer Asset Management Inc. bought a new stake in Atrion in the 4th quarter worth about $148,000. Finally, Legal & General Group Plc increased its holdings in Atrion by 7.8% in the 4th quarter. Legal & General Group Plc now owns 249 shares of the medical instruments supplier’s stock worth $185,000 after buying an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 59.94% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: How do investors use RSI to grade stocks?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.